Zeria Pharmaceutical Co Ltd (4559):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zeria Pharmaceutical Co Ltd (4559) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3325
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zeria Pharmaceutical Co Ltd (Zeria), formerly Zeria Yakusho Kenkyusho Co Ltd is a pharmaceutical company that manufactures pharmaceutical and non-pharmaceuticals, veterinary pharmaceuticals, industrial chemicals and reagents. The company imports and exports healthcare products such as cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, among others It offers ethical products such as therapeutic agents for functional dyspepsia, ulcerative colitis, gastritis and ulcers, hypophosphatemia, proton pump inhibitor, and others. Zeria offers OTC drugs, remedies for gastrointestinal diseases, cold remedies, ophthalmic solutions, anti-inflammatory and analgesics, and hemorroidal remedies, and others. The company owns production structures including Saitama Plant, the Tsukuba Plant, IONA’s Fukushima Plant, Tillotts Pharma’s Ziefen Plant, ZPD’s Esbjerg Plant and F.T. Pharma’s Cat Lai Plant. It has operations in Switzerland, Denmark, Sweden, Ireland, the UK, Czech Republic, Spain, Germany, and other countries. Zeria is headquartered in Tokyo, Japan.

Zeria Pharmaceutical Co Ltd (4559) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Tillotts Pharma Acquires Entocort from AstraZeneca 10
Venture Financing 11
Cancer Prevention Pharma Raises US$0.4 Million In Venture Financing 11
Partnerships 12
Cancer Prevention Pharma Enters into Partnership with National Cancer Institute and Vanderbilt University Medical Center 12
PendoPharm Enters into Distribution Agreement with Tillotts Pharma 13
Solid Form Solutions Enters Into Co-Promotion Agreement With Tillotts Pharma 14
Licensing Agreements 15
Sucampo Enters into Licensing Agreement with Cancer Prevention Pharma 15
Zeria Pharma Enters into Licensing Agreement with Vifor Pharma 16
Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 17
Tillotts Pharma Enters into Licensing Agreement with Inven2 18
Sucampo Pharma Enters into Option Agreement with Cancer Prevention Pharma 19
Tillotts Pharma Enters into Licensing Agreement with Numab 20
Tillotts Pharma Amends Licensing Agreement with Cancer Prevention Pharma 21
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 23
Equity Offering 24
Cancer Prevention Pharma Withdraws IPO for up to USD17.5 Million 24
Debt Offering 26
Cancer Prevention Pharma Raises USD2.3 Million in Private Placement of Notes Due 2018 26
Acquisition 27
Zeria Pharma Acquires Remaining 15% Stake In ZPD From Rorvig 27
Zeria Pharmaceutical Co Ltd – Key Competitors 28
Zeria Pharmaceutical Co Ltd – Key Employees 29
Zeria Pharmaceutical Co Ltd – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 32
Financial Announcements 32
May 12, 2017: Zeria Pharmaceutical Reports Fiscal 2017 Financial Results 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zeria Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Tillotts Pharma Acquires Entocort from AstraZeneca 10
Cancer Prevention Pharma Raises US$0.4 Million In Venture Financing 11
Cancer Prevention Pharma Enters into Partnership with National Cancer Institute and Vanderbilt University Medical Center 12
PendoPharm Enters into Distribution Agreement with Tillotts Pharma 13
Solid Form Solutions Enters Into Co-Promotion Agreement With Tillotts Pharma 14
Sucampo Enters into Licensing Agreement with Cancer Prevention Pharma 15
Zeria Pharma Enters into Licensing Agreement with Vifor Pharma 16
Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 17
Tillotts Pharma Enters into Licensing Agreement with Inven2 18
Sucampo Pharma Enters into Option Agreement with Cancer Prevention Pharma 19
Tillotts Pharma Enters into Licensing Agreement with Numab 20
Tillotts Pharma Amends Licensing Agreement with Cancer Prevention Pharma 21
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 23
Cancer Prevention Pharma Withdraws IPO for up to USD17.5 Million 24
Cancer Prevention Pharma Raises USD2.3 Million in Private Placement of Notes Due 2018 26
Zeria Pharma Acquires Remaining 15% Stake In ZPD From Rorvig 27
Zeria Pharmaceutical Co Ltd, Key Competitors 28
Zeria Pharmaceutical Co Ltd, Key Employees 29
Zeria Pharmaceutical Co Ltd, Other Locations 30
Zeria Pharmaceutical Co Ltd, Subsidiaries 31

List of Figures
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Zeria Pharmaceutical Co Ltd (4559):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • University of California San Diego-医療機器分野:企業M&A・提携分析
    Summary University of California San Diego (UCSD), a subsidiary of University of California, is a public research university that offers education and research with a portfolio of undergraduate, graduate, postdoctoral and professional schools. It offers courses in various fields including arts and h …
  • MDF Instruments Direct, Inc.:企業の戦略的SWOT分析
    MDF Instruments Direct, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Teco Energy Inc-エネルギー分野:企業M&A・提携分析
    Summary TECO Energy Inc (TECO), a subsidiary of Emera Inc., is an energy holding company for regulated electricity and gas utilities and other businesses. It generates, transmits, distributes, purchases and sells electricity; and purchases, distributes and sells natural gas through its subsidiaries. …
  • Marine Corps Community Services:企業の戦略・SWOT・財務情報
    Marine Corps Community Services - Strategy, SWOT and Corporate Finance Report Summary Marine Corps Community Services - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Andrew Peller Limited:企業の戦略・SWOT・財務分析
    Andrew Peller Limited - Strategy, SWOT and Corporate Finance Report Summary Andrew Peller Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Florida Power & Light Co:電力:M&Aディール及び事業提携情報
    Summary Florida Power & Light Company (FPL), a subsidiary of NextEra Energy, Inc., is a vertically-integrated electric utility that generates, transmits and distributes electricity. The company generates electricity from oil, natural gas, coal, nuclear and solar sources. It also purchases power and …
  • Blonder Tongue Laboratories, Inc. (BDR):企業の財務・戦略的SWOT分析
    Blonder Tongue Laboratories, Inc. (BDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • RCS MediaGroup SpA (RCS):企業の財務・戦略的SWOT分析
    RCS MediaGroup SpA (RCS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Recreational Equipment Inc:企業の戦略・SWOT・財務情報
    Recreational Equipment Inc - Strategy, SWOT and Corporate Finance Report Summary Recreational Equipment Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Steris Plc (STE):医療機器:M&Aディール及び事業提携情報
    Summary Steris Plc (Steris), formerly Steris Ltd is a medical equipment company that provides infection prevention and other procedural products. The company offers products such as OR integration systems, sterilizers, surgical tables and lights, perioperative solutions, endoscopy accessories and ba …
  • Rosenergoatom Concern JSC:企業の戦略的SWOT分析
    Rosenergoatom Concern JSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • PDF Solutions Inc (PDFS):企業の財務・戦略的SWOT分析
    Summary PDF Solutions Inc (PDF Solutions) is a technology company that offers yield improvement technologies and services for the IC manufacturing process life cycle. The company offers products such as Exensio Control, Exensio Yield, Exensio Test, Exensio Char, Yield Ramp Simulator and Circuit Surf …
  • Novartis Pharmaceuticals Corp:企業のM&A・事業提携・投資動向
    Novartis Pharmaceuticals Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Novartis Pharmaceuticals Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Main Line Health System:企業の戦略的SWOT分析
    Main Line Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Regulus Therapeutics Inc (RGLS):企業の財務・戦略的SWOT分析
    Summary Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target micr …
  • B. Braun Melsungen AG:企業の戦略的SWOT分析
    B. Braun Melsungen AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Karus Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Karus Therapeutics Ltd (Karus) is a designer and developer of molecule cancer therapies. The company provides treatment of a diverse range of solid and hematological cancers and small molecule drug. It develops two clinic-tracked programs potent and selective inhibitors of PI3K and HDAC for …
  • Beacon Biomedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Beacon Biomedical Inc (Beacon) is a medical diagnostic device company that offers point-of-care blood test systems. The company offers its product portfolio in the therapeutic areas of breast cancer, colorectal cancer and lung cancer. It holds two patented technologies such as signaling prot …
  • Aesica Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Aesica Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • DPL Inc:企業の戦略的SWOT分析
    DPL Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆